PHAT — Phathom Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $592.96m
- $656.34m
- $0.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 869.44 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.61% | ||
| Return on Equity | n/a | ||
| Operating Margin | -24532.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.68 | 44.81 | 173.66 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Directors
- Tadataka Yamada NEC (76)
- Terrie Curran PRE (52)
- Azmi Nabulsi CFD (61)
- David Socks CFD (46)
- Anthony Guzzo CFO
- Michael Cola IND (61)
- Heidi Kunz IND (67)
- Asit Parikh IND (49)
- Mark Stenhouse IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 9th, 2018
- Public Since
- October 25th, 2019
- No. of Shareholders
- 46
- No. of Employees
- 452
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 58,477,351
- Address
- 100 Campus Drive, Suite 102, FLORHAM PARK, 07932
- Web
- https://www.phathompharma.com/
- Phone
- +1 3026365400
- Auditors
- Ernst & Young LLP
Upcoming Events for PHAT
Phathom Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Phathom Pharmaceuticals Inc Earnings Release
Similar to PHAT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Phathom Pharmaceuticals share price?
As of Today at 19:16 UTC, shares in Phathom Pharmaceuticals are trading at $10.14. This share price information is delayed by 15 minutes.
How has the Phathom Pharmaceuticals share price performed this year?
Shares in Phathom Pharmaceuticals last closed at $10.14 and the price had moved by -4.34% over the past 365 days. In terms of relative price strength the Phathom Pharmaceuticals share price has underperformed the S&P500 Index by -22.75% over the past year.
What are the analyst and broker recommendations for Phathom Pharmaceuticals?
The overall consensus recommendation for Phathom Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Phathom Pharmaceuticals dividend yield?
Phathom Pharmaceuticals does not currently pay a dividend.
Does Phathom Pharmaceuticals pay a dividend?
Phathom Pharmaceuticals does not currently pay a dividend.
When does Phathom Pharmaceuticals next pay dividends?
Phathom Pharmaceuticals does not currently pay a dividend.
How do I buy Phathom Pharmaceuticals shares?
To buy shares in Phathom Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Phathom Pharmaceuticals?
As of the previous close price of $10.14, shares in Phathom Pharmaceuticals had a market capitalisation of $592.96m.
Where are Phathom Pharmaceuticals shares listed?
Here are the trading details for Phathom Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PHAT
What kind of share is Phathom Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Phathom Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Phathom Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Phathom Pharmaceuticals is $22.71. That is 123.96% above the last closing price of $10.14.
Analysts covering Phathom Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.57 for the next financial year.
What is the trend in the Phathom Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Phathom Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -14.21%.
As of the last closing price of $10.14, shares in Phathom Pharmaceuticals were trading -2.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Phathom Pharmaceuticals PE Ratio?
The Phathom Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Phathom Pharmaceuticals?
Phathom Pharmaceuticals' management team is headed by:
- Tadataka Yamada - NEC
- Terrie Curran - PRE
- Azmi Nabulsi - CFD
- David Socks - CFD
- Anthony Guzzo - CFO
- Michael Cola - IND
- Heidi Kunz - IND
- Asit Parikh - IND
- Mark Stenhouse - IND